Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus Chemotherapy in LAR Subtype TNBC with PAM Mutation
NCT05954442Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of everolimus in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Sep 2023; status: recruiting.
02
Drugs
everolimus
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05954442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05954442.